Merck starts recruitment for COVID-19 vaccine trial
United States drugmaker Merck Co's vaccine candidate is based on a modified measles virus that delivers bits of the novel coronavirus into the body to prevent COVID-19.12-09-2020
12-09-2020
Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On September 15, 2020
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/09/2020 ,inter alia, to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30, 2020 and to consider recommendation of dividend (if any).07-09-2020
Merck CEO Kenneth Frazier sees human trials for COVID-19 vaccine candidate 'fairly soon'
Merck this year bought Austrian vaccine maker Themis Bioscience to gain its vaccine project that relies on a measles vector, and is also collaborating with research nonprofit IAVI on a second vaccine hopeful that uses the same technology as Merck's Ebola vaccine ERVEBO.03-09-2020
Procter & Gamble Health Ltd - 500126 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed the annual secretarial compliance report for the year ended June 30, 2020, in line with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019. Kindly take the same on record and oblige.28-08-2020
Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by our Registrars and Share Transfer Agent, KFin Technologies Private Limited about the issue of duplicate share certificates as detailed in the attachment.26-08-2020
Merck plans large trials of antiviral Covid-19 drug in September
Merck's research chief Roger Perlmutter said the company has secured manufacturing capability to make 'many millions of doses' of the drug before year end. The experimental drug is currently in phase 2 trials31-07-2020
Procter & Gamble Health Ltd - 500126 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate under Regulation 74(5) SEBI (Depositories and Participants) Regulations, 2018 for the period January 2019 to June 2020.28-07-2020
Procter & Gamble Health Ltd - 500126 - Certificate Under Regulation 40(9) Of The SEBI Listing Regulations For The Period Ended June 30, 2020
We are enclosing herewith Certificate under Regulation 40(9) of the SEBI Listing Regulations for the period ended June 30, 2020.23-07-2020
Procter & Gamble Health Ltd - 500126 - Compliance Certificate As Per Regulation 7(3) For The Period Ended June 30, 2020
We are enclosing herewith compliance certificate as per Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the period ended June 30, 2020.23-07-2020
Double-shot Covid vaccine tests raise new pandemic challenge
Oxford-AstraZeneca and Moderna are leaning on two-dose shots, but US' Merck pins its hope on one shot21-07-2020